Activity of omadacycline tested against Enterobacteriaceae causing urinary tract infections from a global surveillance program (2014)

Diagnostic Microbiology and Infectious Disease

Volumn 91, Issue 2, 2018, Pages 179-183

  Pfaller, M A ^a,b   Rhomberg, P R ^a   Huband, M D ^a   Flamm, R K ^a  

^a JMI LABORATORIES   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Enterobacteriaceae; Omadacycline; Urinary tract infections

Indexed keywords

ANTIINFECTIVE AGENT; OMADACYCLINE; TETRACYCLINE DERIVATIVE;

COHORT ANALYSIS; DRUG EFFECT; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; URINARY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; COHORT STUDIES; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; TETRACYCLINES; URINARY TRACT INFECTIONS;

EID: 85044114850     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2018.01.019     Document Type: Article

References (22)

1. Almer, L.S., Hoffrage, J.B., Keller, E.L., Flamm, R.K., Shortridge, V.D., In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms. Antimicrob Agents Chemother 48 (2004), 2771–2777.
2. Clinical and Laboratory Standards Institute (CLSI), M07-A10. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard—tenth edition. 2015, Clinical and Laboratory Standards Institute, Wayne, PA.
3. Clinical and Laboratory Standards Institute (CLSI), M100-S26. Performance standards for antimicrobial susceptibility testing: 26th informational supplement. 2016, Clinical and Laboratory Standards Institute, Wayne, PA.
4. Draper, M.P., Weir, S., Macone, A., Donatelli, J., Trieber, C.A., Tanaka, S.K., et al. Mechanism of action of the novel aminomethylcycline antibiotic omadacycline. Antimicrob Agents Chemother 58 (2014), 1279–1283.
5. Flamm, R.K., Rhomberg, P.R., Huband, M.D., Farrell, D.J., In vitro activity of delafloxacin tested against isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob Agents Chemother 60 (2016), 6381–6385.
6. Gupta, K., Hooton, T.M., Naber, K.G., Wullt, B., Colgan, R., Miller, L.G., et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 52 (2011), e103–e120.
7. Harnett, S.J., Fraise, A.P., Andrews, J.M., Jevons, G., Brenwald, N.P., Wise, R., Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492. J Antimicrob Chemother 53 (2004), 783–792.
8. Honeyman, L., Ismail, M., Nelson, M.L., Bhatia, B., Bowser, T.E., Chen, J., et al. Structure-activity relationship of the aminomethylcyclines and the discovery of omadacycline. Antimicrob Agents Chemother 59 (2015), 7044–7053.
9. Hooton, T.M., Bradley, S.F., Cardenas, D.D., Colgan, R., Geerlings, S.E., Rice, J.C., et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 international clinical practice guidelines from the Infectious Diseases Society of America. Clin Infect Dis 50 (2010), 625–663.
10. Kahlmeter, G., Eco.Sens, An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project. J Antimicrob Chemother 51 (2003), 69–76.
11. Kobayashi, M., Shapiro, D.J., Hersh, A.L., Sanchez, G.V., Hicks, L.A., Outpatient antibiotic prescribing practices for uncomplicated urinary tract infection in women in the United States, 2002-2011. Open Forum Infect Dis, 2015, 10.1093/ofid/ofv133.35.
12. Macone, A.B., Caruso, B.K., Leahy, R.G., Donatelli, J., Weir, S., Draper, M.P., et al. In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline. Antimicrob Agents Chemother 58 (2014), 1127–1135.
13. Magill, S.S., Edwards, J.R., Bamberg, W., Beldavs, Z.G., Dumyati, G., Kainer, M.A., et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med 370 (2014), 1198–1208.
14. Nilius, A.M., Shen, L.L., Hensey-Rudloff, D., Almer, L.S., Beyer, J.M., Balli, D.J., et al. In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone. Antimicrob Agents Chemother 47 (2003), 3260–3269.
15. Noel, G.J., Draper, M.P., Hait, H., Tanaka, S.K., Arbeit, R.D., A randomized, evaluator-blind, phase 2 study comparing the safety and efficacy of omadacycline to those of linezolid for treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 56 (2012), 5650–5654.
16. Perez, F., Villegas, M.V., The role of surveillance systems in confronting the global crisis of antibiotic-resistant bacteria. Curr Opin Infect Dis 28 (2015), 375–383.
17. Remy, J.M., Tow-Keogh, C.A., McConnell, T.S., Dalton, J.M., Devito, J.A., Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: resistance selection and characterization. J Antimicrob Chemother 67 (2012), 2814–2820.
18. Roberts, M.C., Tetracycline therapy: update. Clin Infect Dis 36 (2003), 462–467.
19. Sanchez, G.V., Master, R.N., Karlowsky, J.A., Bordon, J.M., In vitro antimicrobial resistance of urinary Escherichia coli isolates among U.S. outpatients from 2000 to 2010. Antimicrob Agents Chemother 56 (2012), 2181–2183.
20. van Duin, D., Bonomo, R.A., Ceftazidime/avibactam and ceftolozane/tazobactam: second-generation beta-lactam/beta-lactamase inhibitor combinations. Clin Infect Dis 63 (2016), 234–241.
21. Villano, S., Steenbergen, J., Loh, E., Omadacycline: development of a novel aminomethylcycline antibiotic for treating drug-resistant bacterial infections. Future Microbiol 11 (2016), 1421–1434.
22. Zhanel, G.G., Hisanaga, T.L., Laing, N.M., DeCorby, M.R., Nichol, K.A., Weshnoweski, B., et al. Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). Int J Antimicrob Agents 27 (2006), 468–475.